Regulating Patent Offices: Countering Pharmaceutical Hegemony

    Research output: Contribution to journalArticle


    The grant of a patent is not a reward. Rather it is an opportunity for the patent owner to pursue profits using the patent monopoly to exclude competition. Profit-maximising patent owners focus their monopoly powers on markets in which profits are the greatest. In the case of patents over medical products this leads to well known problems of access to medicines for poor people. The costs and abuses of the patent system in the pharmaceutical sector have been persistent and known for a long time, as John Braithwaite�s magisterial 1984 study, Corporate Crime in the Pharmaceutical Industry vividly illustrates. The failure to do anything substantial about these costs and abuses is a function of the power of pharmaceutical transnational corporations (TNCs) and US and EU hegemony over standard-setting in the international patent framework.
    Original languageEnglish
    Pages (from-to)2-14
    Issue number3
    Publication statusPublished - 2008


    Dive into the research topics of 'Regulating Patent Offices: Countering Pharmaceutical Hegemony'. Together they form a unique fingerprint.

    Cite this